LABEC Pharma meets European regulatory guidelines to sell Interleukin Genetics' Heart Health genetic test

Interleukin Genetics, Inc. (NYSE Amex: ILI) and LABEC Pharma, S.L. announced today that LABEC Pharma has met European regulatory guidelines to sell Interleukin Genetics' Heart Health genetic test. The test, which helps to identify individuals at elevated risk for early heart attack, will be marketed to physicians in Spain and Portugal by LABEC Pharma under the product name Cardio Health™.  Samples will be processed at Interleukin Genetics' CLIA-certified laboratory in Waltham, MA and the Company will receive royalties and processing fees for each test sold.

LABEC Pharma will begin selling the Cardio Health™ genetic test in January 2010. The Interleukin Genetics Cardio Health™ test is the first and only genetic test to identify multiple genetic variations that can lead to overproduction of certain chemicals in the body resulting in inflammation. Individuals with certain interleukin genotypes have a statistically significant risk above standard risk factors for heart attack over those individuals without these genetic patterns.

"We are pleased to begin our partnership with LABEC Pharma on distribution of our Cardio Health™ genetic test to the physician community in two European Countries," said Lewis H. Bender, CEO, Interleukin Genetics, Inc. "Physicians will now have the opportunity to identify patients at elevated risk for heart attack due to chronic underlying inflammation and recommend the appropriate action to improve health outcomes."

"The Interleukin Genetics' test is a unique product and has been validated by two independent clinical studies that demonstrated its ability to identify individuals with significantly elevated risk of heart attack," said Javier de Echevarria, CEO, LABEC Pharma, "We are pleased to be able to offer this product to physicians treating Cardiovascular disease in Spain and Portugal and are confident it will provide very useful information to physicians."